Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Discovering novel biomarkers in prostate cancer

Axel Merseburger • 17 Feb 2022
GU Cancers 2022
Genitourinary Cancer Prostate Cancer

Axel S. Merseburger, MD, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, discusses advances in novel biomarkers for precision medicine in prostate cancer, including modern technologies to uncover biomarkers such as whole genome sequencing, circulating tumor cells (CTCs) and cell-free DNA (cfDNA), as well as artificial intelligence (AI). This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Axel Merseburger

1:23
The evolving treatment landscape of mHSPC and mCRPC
Axel Merseburger • 17 Feb 2022
1:10
PRESIDE: investigating continued treatment with enzalutamide in PC following disease progression
Axel Merseburger • 17 Feb 2022
1:37
The impact of COVID-19 on the care of patients with metastatic GU cancers
Axel Merseburger • 17 Feb 2022
1:50
Does it makes a difference which androgen deprivation therapy you use?
Axel Merseburger • 26 Mar 2017

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals